Amgen Ventures

Amgen Ventures operates as the corporate venture capital arm of Amgen, a prominent global biotechnology company. Established to identify and support innovative companies, Amgen Ventures strategically invests in firms developing groundbreaking therapies and technologies aimed at addressing serious diseases. Its investment mandate is closely aligned with Amgen's core therapeutic areas, ensuring a synergistic approach to advancing medical science.

The firm's investment strategy spans a wide range of company stages, from seed-stage startups to more mature late-stage enterprises. This broad approach allows Amgen Ventures to engage with promising ventures at various points in their development lifecycle. Key areas of strategic interest for investment include oncology, inflammation, neuroscience, cardiovascular, and metabolic diseases, reflecting Amgen's own research and development priorities. Typically, initial investments range from $1 million to $10 million, with a clear potential for subsequent follow-on funding as companies progress.

Since its inception in 2004, Amgen Ventures has built a substantial portfolio, demonstrating its long-term commitment to fostering innovation within the biotech ecosystem. As of recent reports, the firm has invested in over 50 companies, showcasing a diverse array of promising ventures. With approximately $400 million under management, Amgen Ventures possesses significant capital to deploy, enabling it to support its portfolio companies through critical development milestones and contribute to the discovery and delivery of new therapeutic solutions. Its role extends beyond mere capital provision, often leveraging Amgen's extensive scientific and operational expertise to assist its portfolio companies.